Pfizer Inc. (PFE)
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking.
Pfizer: Why You Should Double Down Into Q1
Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms. PFE's 2026 guidance reaffirmation is the key near-term catalyst, with management targeting $59.5–$62.5B revenue and $2.8–$3 EPS despite patent expirations. Onshoring high-margin production and aggressive cost-cutting are central to de-risking LOE headwinds and expanding operating margins through 2027.
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
Pfizer PFE is set to report its first-quarter 2026 earnings on May 5, before market open. The Zacks Consensus Estimate for sales and earnings for the first quarter is pegged at $13.82 billion and 74 cents per share, respectively.
Ahead of Pfizer (PFE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Pfizer (PFE) Dipped More Than Broader Market Today
Pfizer (PFE) reached $26.48 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.
Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping their investment outlook.
B. Metzler seel. Sohn & Co. AG Purchases 71,251 Shares of Pfizer Inc. $PFE
B. Metzler seel. Sohn and Co. AG raised its position in Pfizer Inc. (NYSE: PFE) by 12.5% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 639,639 shares of the biopharmaceutical company's stock after acquiring an additional 71,251 shares during the period. B. Metzler seel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Pfizer (PFE) settling at $26.8, representing a -1.87% change from its previous close.
Pfizer Could Surprise Again This Earnings Season (Preview)
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins as lower-margin COVID products fade from its overall revenue mix. The company's pipeline remains robust, with multiple Phase 3 programs and obesity initiatives that could drive long-term growth and offset upcoming patent expirations. Upcoming earnings may exceed expectations again, as analysts remain cautious despite Pfizer's strong track record of outperforming consensus estimates in recent quarters.
Pfizer GLP-1 weight loss drug available for pre-order in China
Pfizer's GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market analysts expect to be worth billions of dollars.
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according to an analyst note on Monday.
